This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., The BIG story is Janus kinase ( JAK ) inhibitors,” Dr. Martin says.
Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD). This new agreement expands upon the commercial agreement that Aslan signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan.
Adding narrowband ultraviolet B phototherapy to treatment with ritlecitinib (Litfulo, Pfizer) in vitiligo may improve patient outcomes. Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Watch Now The Lowdown on Molluscum Nanette B.
Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.
Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.
Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. Both groups had similar proportions of patients with treatment-emergent adverse events (TEAEs).
Adam Friedman, MD, Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC, shares his excitement about chronic spontaneous urticaria (CSU) treatments coming down the pike including remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase inhibitor.
Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.
Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. and Sanofi report. “We
Silverberg, MD, Chief of Pediatric Dermatology for the Mount Sinai Health System in New York, reviews the rationale for treating Molluscum Contagiosum and shares updates on available treatments including disruptive techniques and the newly approved Zelsuvmi (berdazimer topical gel, 10.3% (Zelsuvmi, Ligand) cantharidin (Ycanth, Verrica).
Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% Treatment was well-tolerated and no new safety signals were identified.
Atopic dermatitis (AD) is extremely common, but it can resemble psoriasis, urticaria, non-blistering immunobolus disease, cutaneous lymphoma, and many other skin conditions. Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Watch Now The Lowdown on Molluscum Nanette B.
Consult Healthcare Providers When Necessary : Seek professional advice for persistent, severe, or unusual scalp symptoms to ensure accurate diagnosis and effective treatment. Dandruff (Seborrheic Dermatitis) Dandruff, medically known as seborrheic dermatitis , is a common scalp condition marked by excessive shedding of skin cells.
There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision. A dermatologist can provide personalized recommendations and treatment plans tailored to your child’s specific needs.
Genodermatoses can masquerade as atopic dermatitis (AD). Raj Chovatiya, MD, PhD Atopic dermatitis (AD) is extremely common, but it can resemble psoriasis, urticaria, non-blistering immunobolus disease, cutaneous lymphoma, and many other skin conditions. Watch Now Think Twice: Is It Really AD?
Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.
Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.
Alexis and Kwatra “Seborrheic Dermatitis in Skin of Color” with Drs. The 20th Annual SOCS Scientific Symposium was generously supported by the following sponsors: AbbVie, Johnson & Johnson, Sanofi and Regeneron Pharmaceuticals, Inc. Adotama and Luke “A Fresh Look at Aging” with Drs.
Single-cell profiling of alopecia areata (AA) can provide key insights into immune-targeting treatment strategies. Raj Chovatiya, MD, PhD Atopic dermatitis (AD) is extremely common, but it can resemble psoriasis, urticaria, non-blistering immunobolus disease, cutaneous lymphoma, and many other skin conditions.
Raj Chovatiya, MD, PhD Atopic dermatitis (AD) is extremely common, but it can resemble psoriasis, urticaria, non-blistering immunobolus disease, cutaneous lymphoma, and many other skin conditions. Watch Now Pro Pearls for Diagnosing Genodermatoses Elizabeth Swanson, MD Genodermatoses can masquerade as atopic dermatitis (AD).
Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale University in New Haven, CT, shares some congenital ichthyosis (CI) cases and discusses the importance of understanding patient and family expectations about CI treatment.
Chronic spontaneous urticaria (CSU) often has no identifiable trigger and is driven by mast cells, but symptoms are bothersome to patients, highlighting the need for effective treatments, says Jason Hawkes, MD, MS, a dermatologist in Rocklin, CA.
Watch Now [the_ad id="9263"] [the_ad id="9265"] Pro Pearls for Diagnosing Genodermatoses Elizabeth Swanson, MD Genodermatoses can masquerade as atopic dermatitis (AD). Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, shares three pearls on how to make these important differential diagnoses.
Over the years, retinol has been touted as the holy grail anti-aging treatment by almost every dermatologist and skin care expert…it is often recommended as the “must-have” active ingredient in your skin care routine. Bakuchiol – Vegan Retinol – What is all the hype about?
Watch Now Off-label Pearl: Exploring the Role of Narrowband UVB Phototherapy Plus Oral JAK Inhibitors in Vitiligo Emma Guttman-Yassky, MD, PhD Adding narrowband ultraviolet B phototherapy to treatment with ritlecitinib (Litfulo, Pfizer) in vitiligo may improve patient outcomes. Watch Now The Lowdown on Molluscum Nanette B.
AD: New topicals for kids “The most exciting new research is in the realm of topical therapies for atopic dermatitis (AD) in children,” shares Peter A. In a second study, treatment with ruxolitinib cream under maximum-use conditions was well tolerated in same-aged kids for eight weeks.
AD: New topicals for kids “The most exciting new research is in the realm of topical therapies for atopic dermatitis (AD) in children,” shares Peter A. In a second study, treatment with ruxolitinib cream under maximum-use conditions was well tolerated in same-aged kids for eight weeks.
In this era of readily available pharmaceutical products for every imaginable ailment, it can be easy to default to the drug store when we need relief. Medieval Persian pharmaceutical manuscripts refer to 1200 types of oxymel. It has not always been that way. Reposted from: [link]
Here’s a review of 10 natural antimicrobials you can reach for as a first line of defense, before resorting to a pharmaceutical antibiotic. Department of Health proposed guidelines recommending the use of honey as a first line of treatment for coughs, as part of its goal to reduce inappropriate antibiotic use. In 2018, the U.K.
Alys Pharmaceuticals, Inc. Alys combines six asset-centric Medicxi companies including Al Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. ” The post Get to Know Alys Pharmaceuticals, Inc. appeared first on The Dermatology Digest.
Shared-decision making focused on weighing risks versus benefits is key when choosing the most appropriate systemic atopic dermatitis (AD) treatment for a patient, according to new research presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC. some of the JAK inhibitors).
Jerry Tan, MD, is joining Derm-Biome Pharmaceuticals, Inc.’s Acne is a very common skin disease, but there is still a real unmet need for treatments that are both well-tolerated and effective. s Scientific Advisory Board.
Elisabeth Richard discusses phototherapy in today’s practice, including usage trends, its continued role in the treatment of numerous skin diseases, and the importance of continuing to offer it to patients as a therapeutic option. When I’m counseling patients I tell them a clearance course is typically about 25 to 30 treatments.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content